Neanderthal-derived genetic locus influences COVID-19 severity in humans

Researchers in the United States and Estonia have identified four genetic variants on a chromosome 3 haplotype that may be responsible for driving the association between this locus and the severity of coronavirus disease 2019 (COVID-19).

Research has previously shown that this haplotype, which entered the human population via introgression from Neanderthals, is the most decisive genetic risk factor for severe COVID-19.

“However, the specific variants along this introgressed haplotype that contribute to this risk and the biological mechanisms that are involved remain unclear,” writes the team from Harvard University in Cambridge, Massachusetts and the University of Tartu in Estonia.

Now, Terence Capellini and colleagues have identified four introgressed alleles that are strong functional candidates for driving the association between this locus and severe COVID-19.

The researchers say the variants likely drive the impact on severity by modulating the regulation of two critical chemokine receptor genes: CCR1 and CCR5.

“These alleles are ideal targets for future functional investigations into the interaction between host genomics and COVID-19 outcomes,” they write.

A pre-print version of the research papers is available on the bioRxiv* server, while the article undergoes peer review.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Patient phenotypes following SARS-CoV-2 infection are wide-ranging

Since the COVID-19 outbreak began in late December 2019, the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – has infected more than 176 million people and claimed the lives of more than 3.81 million globally.

Infected individuals present with a wide variety of phenotypes, ranging from asymptomatic disease in some individuals to severe and even fatal outcomes in others.

This wide range of phenotypes is partly accounted for by the presence of comorbidities, but underlying health conditions do not fully explain the variation in patient outcomes.

Research efforts have therefore also focused on the role of potential genetic components.

Previous research identified a genetic haplotype on chromosome 3 that entered the human population via introgression from Neanderthals as the strongest genetic risk factor for severe COVID-19.

This chromosomal region, which includes a cluster of chemokine receptor genes, has repeatedly been associated with increased COVID-19 severity among Europeans. The strongest reported risk variant is shown to increase the likelihood of hospitalization by 88%.

One 2020 study reported that the core introgressed haplotype spans around 49 kilobases (kb) from chromosome 3 (chr3):45859651to 45909024 and that a broader haplotype spans around 333kb from chr3:45843315 to 46177096.

“However, the specific phenotypic consequences of this haplotype leading to its potential adaptive effect as well as its effect on COVID-19 severity remain unknown,” says Capellini and colleagues. “Moreover, the potential causal drivers of this selection, as well as COVID-19 severity remain unstudied.”

What did the researchers do?

The researchers examined the haplotype in the context of a broader introgressed segment spanning around 811kb from chr3:45843242- 46654616. They identified 613 variants that were then tested as potential drivers of the association between this region and increased COVID-19 severity.

Next, Capellini and colleagues performed a high-throughput functional massively parallel reporter assay (MPRA) that identified 20 alleles along the introgressed segment that directly modulated reporter gene expression.

Finally, the researchers intersected these 20 alleles with a host of molecular and phenotypic datasets, which ultimately identified four introgressed alleles that showed the strongest evidence of driving the association between this locus and severe COVID-19.

“These shortlisted variants primarily modulate expression through their potential effects on CCR1 and CCR5 cis-regulation and are strong candidate variants that should be investigated with future targeted functional experiment,” writes the team.

Further studies are needed

The researchers say that while the study provides strong functional support for at least four archaic variants at the introgressed locus, the direction of the effect of these alleles in both the healthy and infected state needs further clarification.

For example, in studies of severe COVID-19, CCR1 and CCR5 have been shown to be upregulated compared with moderate cases of the disease. However, in the MPRA experiments here, the three top candidate expression-modulating variants acting as regulators of CCR1 were all downregulated.

The team hypothesizes that this difference between the alleles’ direction of effect in the healthy versus disease state reflects that these alleles contribute to the risk of severe COVID-19 by destabilizing the regulatory mechanism of CCR1 and CCR5, such that they have decreased expression in the healthy state, but are hyper-expressed following infection.

“Additional work needs to be done to further explore this potential mechanism, as well as to uncover what therapeutic roots may be undertaken to mitigate this mechanism, should it be found to be accurate,” concludes the team.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, April 10). Neanderthal-derived genetic locus influences COVID-19 severity in humans. News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/news/20210615/Neanderthal-derived-genetic-locus-influences-COVID-19-severity-in-humans.aspx.

  • MLA

    Robertson, Sally. "Neanderthal-derived genetic locus influences COVID-19 severity in humans". News-Medical. 23 November 2024. <https://www.news-medical.net/news/20210615/Neanderthal-derived-genetic-locus-influences-COVID-19-severity-in-humans.aspx>.

  • Chicago

    Robertson, Sally. "Neanderthal-derived genetic locus influences COVID-19 severity in humans". News-Medical. https://www.news-medical.net/news/20210615/Neanderthal-derived-genetic-locus-influences-COVID-19-severity-in-humans.aspx. (accessed November 23, 2024).

  • Harvard

    Robertson, Sally. 2023. Neanderthal-derived genetic locus influences COVID-19 severity in humans. News-Medical, viewed 23 November 2024, https://www.news-medical.net/news/20210615/Neanderthal-derived-genetic-locus-influences-COVID-19-severity-in-humans.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes